Bolt Biotherapeutics Inc Ordinary Shares BOLT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
INVESTIGATION ALERT - The M&A Class Action Firm Is Investigating the Merger - RRC, SGRY, BOLT and PCRX - IS IT A FAIR DEAL FOR YOU?
Bolt Biotherapeutics to Participate in Upcoming Conferences
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT)
Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory Indications
Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Trading Information
- Previous Close Price
- $6.38
- Day Range
- $6.29–6.34
- 52-Week Range
- $3.12–7.62
- Bid/Ask
- $6.29 / $6.53
- Shares Outstanding
- 2.36M
- Market Cap
- $14.85M
- Volume/Avg
- 545 / 245,257
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.38
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 23
- Website
- https://www.boltbio.com
Valuation
Metric | BOLT |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.97 |
Price/Sales | 2.38 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | BOLT |
|---|---|
Quick Ratio | 2.24 |
Current Ratio | 2.61 |
Interest Coverage | — |
Quick Ratio
BOLT
Profitability
Metric | BOLT |
|---|---|
Return on Assets (Normalized) | −42.55% |
Return on Equity (Normalized) | −93.56% |
Return on Invested Capital (Normalized) | −52.35% |
Return on Assets
BOLT
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|N!XLXTh | LOCK|&<jR | $138B | |||
| Moderna Inc MRNA | LOCK|bsw><H^ | LOCK|h?w | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|mj@yxX | LOCK|RqPf | $93B | |||
| argenx SE ADR ARGX | LOCK|vTQ@@%& | LOCK|hB< | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|Vlc!Fd | LOCK|jz | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|Q^M^LdGz | LOCK|kn<< | $30B | |||
| Incyte Corp INCY | LOCK|WDf?T@ | LOCK|S< | $24B | |||
| BioNTech SE ADR BNTX | LOCK|!#ffN$z | LOCK|Pl | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|z>CtLVV | LOCK|XkkT | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|PGV<hcH | LOCK|gp$ | $15B |
United States